Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Featured Products > Oncology Research > Bladder Cancer

Bladder Cancer Research Reagents

Bladder cancer is the tenth most common cancer worldwide, with urothelial carcinoma accounting for approximately 90% of cases. Molecular subtypes (luminal vs. basal-squamous) predict differential responses to chemotherapy and immunotherapy. Treatment has been transformed by immune checkpoint inhibitors, antibody-drug conjugates (enfortumab vedotin targeting Nectin-4), and FGFR inhibitors (erdafitinib) for FGFR2/3-altered tumors.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Bladder Cancer Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets in bladder cancer. Nectin-4 ADC targeting, FGFR3 signaling, and PD-1/PD-L1 immune checkpoint. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key bladder cancer research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

Nectin-4 (PVRL4) — Nectin-4 is an adhesion molecule highly expressed on urothelial carcinoma cells and the target for enfortumab vedotin (ADC). Anti-Nectin-4 antibodies enable IHC expression profiling, ADC internalization studies, and patient stratification in urothelial cancer treatment research.
→ Browse Nectin-4 antibodies & proteins

FGFR3 — FGFR3 activating mutations and fusions occur in approximately 15–20% of advanced urothelial carcinoma and predict sensitivity to erdafitinib. Anti-FGFR3 antibodies support IHC expression analysis, mutation-associated overexpression detection, and FGFR signaling pathway studies.
→ Browse FGFR3 antibodies & proteins

PD-L1 (CD274) — PD-L1 expression guides immunotherapy selection in urothelial carcinoma, with different scoring algorithms (IC for atezolizumab, CPS for pembrolizumab). Anti-PD-L1 antibodies support expression scoring validation and combination immunotherapy optimization research.
→ Browse PD-L1 antibodies & proteins

References

1. Powles T, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218-1230. DOI

2. Powles T, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875-888. DOI

3. Loriot Y, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348. DOI

4. Robertson AG, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-556. DOI

392 product results for "Bladder Cancer"

Options+
Options
Confirm
  • Product types
    0 selected
    Antibodies (175)
    Research Biosimiliar (6)
    Proteins (50)
    Stable Cell Lines (3)
    Assay Kit (1)
    Research Biosimilar (157)
  • Expression system
    0 selected
    HEK293T (3)
    Mammalian cells (175)
    E. coli (20)
  • Target
    0 selected
    TP63/p40/NP63 (2)
    EGFR & CD3E & PD-L1 & 4-1BB (1)
    CD340/ERBB2 (90)
    CD340/ERBB2/HER2 (6)
    TACSTD2/TROP2 (33)
    CD274/PD-L1 & CD134/OX40 (1)
    CD340/ERBB2 & CD279/PD-1 (1)
    CD172a/SIRPA & CD340/ERBB2 (1)
    CD274/PD-L1 & CD137/TNFRSF9 (1)
    CD274/PD-L1 & TGFBR2 (1)
    CD274/PD-L1 & TGFBR2/TGFR-2 (1)
    CD366/TIM-3 & CD274/PD-L1 (1)
    PD-L1 / VEGF-A (1)
    CD274/PD-L1 & SLT-Ia (1)
    CD47/MER6 & PDCD1 / PD-1 & CD137/4-1BB/TNFRSF9 (1)
    CD19 & PD-L1 & CD3E & CD137 (1)
    Fluorescein & CD274/PD-L1 (1)
    UPK1A (1)
    VEGFA & B7-H1 / PD-L1 / CD274 (1)
    TACSTD2/TROP2 & HSG (1)
    UPK1B (2)
    CD137/4-1BB & CD274/PD-L1 (3)
    CD340/ERBB2 & CD3E (5)
    CD47/MER6 & CD274/PD-L1 (2)
    CD137/4-1BB & CD340/ERBB2 (2)
    CD47/MER6 & CD274/PD-L1/B7-H1 (2)
    UPK3A (4)
    ERBB2 / HER2 / CD340 & CD137/4-1BB/TNFRSF9 (1)
    ERBIN (2)
    CD340/ERBB2 & CD3 (1)
    CD152/CTLA4 & CD274/PD-L1 (1)
    PD-L1 & VEGF (1)
    PDL1 & VEGF (1)
    KRT5 (4)
    TROP2/TACSTD2/TROP-2 (1)
    MAPK4 (1)
    CD274/PD-L1 & CD279/PD-1 (1)
    CD274/PD-L1 & CD3E (1)
    CD274/PD-L1 & VEGFA (1)
    4-1BB & FAP (1)
    TIGIT & CD274/PD-L1 (1)
    CD340/ERBB2/HER2 & CD3E (1)
    CD274/PD-L1 & CD28 (1)
    PD-L1 & TGF-Beta (1)
    CD274/PD-L1/B7-H1 (5)
    CD333/FGFR3 (17)
    CKAP4 (4)
    CD137/4-1BB/TNFRSF9& CD274/PD-L1/B7-H1 (1)
    NECTIN4/PVRL4 (30)
    4-1BB & HER2 (1)
    CD279/PD-1 & CD274/PD-L1 (1)
    Spike glycoprotein (1)
    KRT20 (2)
    CD340/ERBB2/HER2&CD314/KLRK1/NKG2D (1)
    CD47/MER6 & PDCD1 / PD-1 / CD279 (1)
    CD274/PD-L1 (81)
    UVRAG (1)
    GATA3 (5)
    PD-1 & CD3E (1)
    PDL1 (6)
    UPK2/Uroplakin 2 (2)
    VSIR/VISTA & CD274/PD-L1 (1)
    CD332/FGFR2 (21)
    CD274/PD-L1 & CD28 & CD152/CTLA4 (1)
    CD137/4-1BB & CD274/PD-L1 & ROR1 & CD3 (1)
    CD274/PD-L1 & CD152/CTLA4 (1)
    HER2 (domain III) (1)
    FLT1/VEGFR1 & CD274/PD-L1 (1)
    CD274/PD-L1 & CD47/MER6 (1)
    CD340/ERBB2 & ERBB3/HER3 (1)
  • Species
    0 selected
    Homo sapiens (Human) (4)
    Human (182)
    Tupaia chinensis (3)
    Cat (1)
    Mouse (15)
    Felis catus (Cat) (2)
    Mus musculus (Mouse) (9)
    Dog (5)
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1)
  • Applications
    0 selected
    Functional assay (12)
    Neutralization (1)
    Blocking (3)
    Bioactivity: FACS (1)
    ELISA (307)
    ICC (1)
    Immunogen (50)
    Bioactivity: FACS (152)
    Research in vivo (2)
    FuncS (13)
    SDS-PAGE (50)
    Bioactivity testing in progress (33)
    Functional assay (155)
    in vivo PD-L1 blockade (3)
    WB (112)
    Research in vivo (155)
    in vitro PD-L1 blockade (3)
    IHC (45)
    IF (6)
    IHC-F (3)
    FACS (11)
    FCM (101)
    in vivo blockade (2)
  • Reactivity
    0 selected
    Rat (6)
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1)
    Cat (1)
    NECTIN4/PVRL4 (1)
    Mus musculus (1)
    Rattus norvegicus (1)
    Homo sapiens (Human) (2)
    Mus musculus (Mouse) (1)
    Mouse (35)
    Homo sapiens (1)
    Bos taurus (1)
    Tupaia chinensis (1)
    Chicken (1)
    Human (267)
    Pan troglodytes (1)
    B7-H1 / PD-L1 / CD274 (1)
    Cynomolgus (1)
  • Host species
    0 selected
    Chimeric (3)
    HEK293T (3)
    Mouse (88)
    Alpaca (7)
    Human (201)
    Rabbit (26)
    Rat (7)
  • Clonality
    0 selected
    Polyclonal (24)
    Monoclonal (309)
  • Conjugate
    0 selected
    PerCP (18)
    FITC (18)
    PE (18)
    Unconjugated (241)
    APC (18)

Quick access

Contact Us

  • +86-27-87433958

  • info@abinscience.com

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only